Ribo reports vortosiran Phase IIa trial results for coronary artery disease
Patients completing the high-dose cohort achieved a 92% average reduction in FXI activity for several months.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance